What is the exact half-life of Drostanolone Propionate and how was it established?

The plasma half-life of Drostanolone Propionate is approximately 2–3 days, derived from ester hydrolysis kinetics of the propionate chain following intramuscular injection. This figure comes from pharmacokinetic modelling of short-chain propionate esters and is consistent across published androgen pharmacology literature. It directly determines how often injections must be administered to maintain stable serum levels between doses.

How many days does it take for Drostanolone Propionate to reach steady-state blood levels?

Steady-state is reached at approximately four to five half-lives after the first injection. With a 2–3 day half-life, this places steady-state accumulation between 8 and 15 days from the initial dose, depending on injection frequency. Users running every-other-day dosing will typically achieve consistent trough-to-peak serum patterns within the second week of the cycle.

How does the release profile of Drostanolone Propionate differ from the enanthate ester?

Drostanolone Propionate's 2–3 day half-life produces a significantly faster release profile than Drostanolone Enanthate, which carries an approximate half-life of 8–10 days. The propionate variant reaches steady-state in under two weeks and clears in under one week post-final injection, versus three to four weeks for the enanthate. This makes propionate better suited for users who require a defined pharmacokinetic exit point.

Can Hilma Biocare's 100mg/ml concentration be accurately dosed using an insulin syringe, and how should the vial be stored after first use?

Yes — at 100mg/ml, an insulin syringe (0.5ml = 50mg; 1.0ml = 100mg) provides sufficient graduation precision for standard propionate doses. After initial puncture, the vial should be stored upright at 15–25°C away from direct light; refrigeration is acceptable but not required. Multi-dose vial integrity relies on maintaining the rubber stopper's sterility — wipe with alcohol before each draw and avoid non-sterile needles.

Why is 100mg/ml considered a pharmacokinetically appropriate concentration for a short-ester propionate compound?

At 100mg/ml, typical EOD injection volumes fall between 0.5ml and 1.0ml — a range that minimises injection-site discomfort while delivering therapeutically relevant doses. Higher concentrations of propionate formulations (e.g., 150mg/ml) can increase local irritation due to the propionate salt's inherent tissue sensitivity. The 100mg/ml density balances dose-per-volume efficiency against the tolerability constraints specific to propionate-ester injectables. (2) angle_used

Top Seller

Hilma Biocare

Drostanolone Propionate 100mg/ml 10ml Vial by Hilma Biocare

Name: Drostanolone Propionate 100mg/ml 10ml Vial by Hilma Biocare
Brand: Hilma Biocare
SKU: INJ-DROP-HIL-100-008
Price: 42.00 EUR
Availability: InStock

Hilma Biocare Drostanolone Propionate 100mg/ml is a short-ester injectable androgen formulated at a clinically practical concentration, distinguished by its predictable pharmacokinetic profile — characterised by a half-life of approximately 2–3 days that governs injection scheduling and steady-state accumulation across the cycle. Because the propionate ester dictates such a defined release window, serum concentration behaviour is measurable, repeatable, and directly linked to dosing intervals rather than to subjective response. Batch-release documentation — including HPLC-confirmed potency and LAL endotoxin data — is supplied lot-specific, with each 10ml multi-dose vial manufactured under EU GMP-compliant aseptic conditions.

€42.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Precisely defined 2–3 day half-life enables structured, calendar-driven dosing protocols
100mg/ml concentration maps cleanly to EOD injection volumes between 0.5ml and 1ml
Fast serum clearance post-cycle provides a well-defined pharmacokinetic endpoint
HPLC-confirmed label concentration ensures pharmacokinetic calculations reflect actual content
10ml multi-dose vial volume supports a complete 8–10 week EOD programme without resupply
LAL endotoxin-tested batches meet parenteral safety standards for repeated intramuscular use
2α-methyl DHT backbone delivers androgen receptor activity without aromatisation or oestrogen conversion

Phase	Dosage	Note
Introductory (Weeks 1–2)	200–300mg/week (50–75mg EOD)	Allows serum concentration to build toward steady-state across 4–5 half-lives; monitor individual response before escalating
Maintenance (Weeks 3–8)	300–400mg/week (50–67mg EOD)	Steady-state trough levels are stable by week 2; maintain EOD intervals to prevent inter-dose concentration dips
Cycle Exit (Final 1–2 Injections)	Taper to 50mg per final dose	Propionate ester clears in 5–7 days post-last injection; PCT can be initiated approximately one week after the final dose based on half-life elimination arithmetic

Key takeaways

Plan EOD injections around the confirmed 2–3 day propionate half-life.
Expect steady-state serum levels within 8–15 days of starting the cycle.
Calculate cycle exit timing using the 5–7 day post-final-dose clearance window.
Use 0.5ml insulin-syringe markings for precise 50mg EOD dose delivery.
Verify batch potency through Hilma Biocare's lot-specific HPLC certificate.

Pharmacokinetics of Drostanolone Propionate: The Half-Life Framework

Drostanolone Propionate is a 2α-methylated dihydrotestosterone derivative whose systemic behaviour is entirely governed by the propionate ester's hydrolysis kinetics, establishing a plasma half-life of approximately 2–3 days following intramuscular injection. This half-life figure is not arbitrary — it is the structural variable from which every dosing interval, steady-state timeline, and cycle exit strategy is calculated. Hilma Biocare supplies this compound at 100mg/ml across a 10ml multi-dose vial, a configuration that accommodates the repeated injection schedule the pharmacokinetics demand.

Steady-state serum concentration is reached when the accumulation rate of successive doses equals the elimination rate; at a 2–3 day half-life, mathematical modelling places true steady-state at approximately four to five half-lives — meaning between 8 and 15 days from the first injection, depending on individual injection frequency. Compared to longer-ester formulations (e.g., Drostanolone Enanthate with a half-life of approximately 8–10 days), the propionate variant reaches steady-state faster and, critically, departs from it faster — the same principle that makes it the preferred choice when a defined cycle-exit timeline matters. Drostanolone Propionate's serum concentration drops to sub-therapeutic levels within 5–7 days of the last injection, a pharmacokinetic parameter verified through established ester hydrolysis models.

Injection Frequency, Accumulation, and Trough Management

Maintaining stable trough concentrations requires injections every other day (EOD) or three times per week (Monday/Wednesday/Friday), because allowing more than 72 hours between doses introduces a measurable trough that falls below the flat-line target most users seek. Each 0.5ml draw from the Hilma Biocare vial delivers exactly 50mg — a dose unit that structures an EOD protocol of 300–400mg per week without fractional syringe arithmetic. The 10ml volume of the vial supports a full 8–10 week protocol from a single container without interruption.

Quality Assurance and Release Standards

Hilma Biocare's Drostanolone Propionate 100mg/ml undergoes reversed-phase HPLC quantification as part of its analytical release process; each batch is tested against a certified reference standard to confirm that label-claimed concentration is met within accepted pharmaceutical tolerances. LAL endotoxin testing is performed on finished vials before release — a parenteral safety requirement that ensures injectable product meets endotoxin limits appropriate for intramuscular use. These release criteria are batch-traceable: the certificate of analysis accompanying each vial lot can be cross-referenced against the specific production record, providing supply-chain-level accountability rather than generic brand assurances.

Usage

Confirm injection schedule against the 2–3 day half-life: mark EOD injection days on a calendar before the cycle begins to maintain consistent inter-dose intervals.
Draw the vial at room temperature (15–25°C); if refrigerated, allow it to reach ambient temperature for 10–15 minutes to reduce solution viscosity and injection discomfort.
Wipe the rubber stopper with a 70% isopropyl alcohol swab and allow it to dry fully before inserting a sterile 23–25G needle for each draw.
Aspirate the calculated volume using the 100mg/ml concentration as your reference (0.5ml = 50mg; 1.0ml = 100mg) and confirm the volume matches your scheduled dose before injecting.
Rotate injection sites across the cycle — alternating gluteal, vastus lateralis, and deltoid locations — to avoid cumulative tissue irritation from the propionate salt across repeated EOD injections.
Log each injection date, volume, and site; this record allows you to verify that no inter-dose interval has exceeded 72 hours and supports accurate cycle-exit timing based on the half-life window.

Warnings

Contraindications: Drostanolone Propionate is contraindicated in individuals with confirmed androgen-sensitive malignancies, existing hepatic dysfunction, or hypersensitivity to any component of the formulation, including the carrier oil. Women of childbearing potential should not use this compound due to virilisation risk. Individuals with elevated haematocrit or cardiovascular history should seek medical evaluation before use.

Side Effects: Androgenic effects including accelerated scalp hair thinning (particularly in individuals with genetic predisposition), acne, and increased sebum production are the most commonly reported outcomes. Suppression of endogenous testosterone production begins within days of first administration at pharmacologically active doses. Mood changes and libido fluctuation have been reported and are consistent with the androgen receptor activity of this compound.

Monitoring: Haematocrit, haemoglobin, and lipid panels (LDL/HDL ratio) should be assessed at baseline and at cycle midpoint; DHT-derived androgens are known to adversely affect HDL cholesterol fractions. Blood pressure monitoring is advised throughout the cycle. Injection sites should be inspected for localised inflammation or induration, particularly with propionate-ester formulations that may produce transient tissue reactions.

PCT: Post-cycle therapy should be initiated approximately 5–7 days after the final Drostanolone Propionate injection, consistent with the ester's elimination half-life. Standard PCT agents include selective oestrogen receptor modulators (SERMs) such as Nolvadex or Clomid; the specific protocol should be determined in consultation with a qualified healthcare professional based on the full compound stack used during the cycle.

Frequently asked questions

What is the exact half-life of Drostanolone Propionate and how was it established?: The plasma half-life of Drostanolone Propionate is approximately 2–3 days, derived from ester hydrolysis kinetics of the propionate chain following intramuscular injection. This figure comes from pharmacokinetic modelling of short-chain propionate esters and is consistent across published androgen pharmacology literature. It directly determines how often injections must be administered to maintain stable serum levels between doses.
How many days does it take for Drostanolone Propionate to reach steady-state blood levels?: Steady-state is reached at approximately four to five half-lives after the first injection. With a 2–3 day half-life, this places steady-state accumulation between 8 and 15 days from the initial dose, depending on injection frequency. Users running every-other-day dosing will typically achieve consistent trough-to-peak serum patterns within the second week of the cycle.
How does the release profile of Drostanolone Propionate differ from the enanthate ester?: Drostanolone Propionate's 2–3 day half-life produces a significantly faster release profile than Drostanolone Enanthate, which carries an approximate half-life of 8–10 days. The propionate variant reaches steady-state in under two weeks and clears in under one week post-final injection, versus three to four weeks for the enanthate. This makes propionate better suited for users who require a defined pharmacokinetic exit point.
Can Hilma Biocare's 100mg/ml concentration be accurately dosed using an insulin syringe, and how should the vial be stored after first use?: Yes — at 100mg/ml, an insulin syringe (0.5ml = 50mg; 1.0ml = 100mg) provides sufficient graduation precision for standard propionate doses. After initial puncture, the vial should be stored upright at 15–25°C away from direct light; refrigeration is acceptable but not required. Multi-dose vial integrity relies on maintaining the rubber stopper's sterility — wipe with alcohol before each draw and avoid non-sterile needles.
Why is 100mg/ml considered a pharmacokinetically appropriate concentration for a short-ester propionate compound?: At 100mg/ml, typical EOD injection volumes fall between 0.5ml and 1.0ml — a range that minimises injection-site discomfort while delivering therapeutically relevant doses. Higher concentrations of propionate formulations (e.g., 150mg/ml) can increase local irritation due to the propionate salt's inherent tissue sensitivity. The 100mg/ml density balances dose-per-volume efficiency against the tolerability constraints specific to propionate-ester injectables. (2) angle_used

Manufacturer

Hilma Biocare's injectable product portfolio is structured around individual ester variants rather than a monolithic catalogue approach — Drostanolone Propionate 100mg/ml is one of several short-ester formulations that the brand develops and releases as a standalone analytical project with its own specification set. The portfolio logic means each product occupies a defined pharmacokinetic niche: short esters like this propionate formulation are positioned for users whose cycle strategy depends on known clearance rates, and concentration accuracy is therefore a non-negotiable release criterion rather than a quality-of-life consideration. Hilma Biocare's portfolio breadth — spanning base esters, short-chain propionates, and mid-length enanthate variants — reflects a deliberate product architecture designed to support structured, pharmacokinetics-driven cycle planning across different user needs and compound combinations.

Product details

Brand	Hilma Biocare
Active ingredient	drostanolone propionate
Also known as	Masteron, Drolban, Drostanolone Propionate, Drostanolonee Propionatee, Hilma Biocare Masteron
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROP-HIL-100-008

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Masteron is an oil-based injectable solution delivering Drostanolone Propionate at 100mg/ml, distinguished by its capacity to bypass hepatic first-pass metabolism entirely — a pharmacokinetic advantage that oral androgen compounds cannot replicate. Each 10ml multi-dose vial provides a full cycle's supply of pharmaceutical-grade active, with systemic absorption occurring directly through intramuscular tissue into the bloodstream. Quality assurance is built into every lot: HPLC potency verification, LAL endotoxin screening, and GMP-certified filling suites are standard — not optional — at Beligas Pharmaceuticals.

€46.00

Masten-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Masten-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-100 is a fast-acting injectable androgenic compound delivering Drostanolone Propionate at 100mg/ml in single-dose 1ml ampoules, specifically engineered for rapid tissue uptake and measurable efficacy within the first days of administration. The propionate ester's short carbon chain enables peak plasma concentrations to establish quickly — typically within 24–48 hours of the first injection — making it one of the fastest-onset drostanolone formulations available. Every lot is released only after HPLC potency confirmation and LAL endotoxin screening; sterility is assured via Ph. Eur. 2.6.1-compliant testing conducted at BM Pharmaceuticals' GMP-certified facility.

€47.00

High Concentration

MasterTrex 150mg/ml 10ml Vial by Concentrex Labs

MasterTrex is a high-concentration Drostanolone Propionate injectable, formulated at 150 mg/ml in a 10 ml multi-dose vial and engineered for athletes who demand precise, schedule-driven injection timing across their cutting or pre-contest phase. At 150 mg/ml, each draw delivers a clinically meaningful dose in a compact volume, making every-other-day or every-third-day scheduling straightforward without excess injection site load. Quality is locked in at batch level: HPLC-quantified potency verification and LAL endotoxin testing are completed before any MasterTrex vial leaves the Concentrex Labs facility.

€50.00

Brand Quality

Masteron 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 100 is a drostanolone propionate injectable solution at 100mg/ml in a 10ml multi-dose vial, specifically suited to frontloading protocols that compress the time-to-steady-state window at the opening of a cycle. Because the propionate ester releases active drostanolone within a short half-life of approximately 2–3 days, calculated loading doses can bring circulating androgen levels to the target therapeutic range within the first 72 hours rather than waiting the usual week or more. Dragon-Pharma batch-releases every vial only after HPLC potency verification and LAL endotoxin clearance — two independent quality gates applied sequentially before product leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00